Caroline Seymour

Patients with promyelocytic leukemia saw an improved overall survival and relapse-free survival when treated with an all-oral regimen of arsenic trioxide, all-trans retinoic acid, and ascorbic acid.

Amivantamab plus lazertinib may represent a new standard of care in those with EGFR-mutated advanced non–small cell lung cancer, according to Byoung Chul Cho, MD, PhD.

Findings from the phase 3 innovaTV trial support tisotumab vedotin as a potential standard of care for patients with metastatic or recurrent cervical cancer following disease progression.

Amivantimab produces superior progression-free survival in EGFR exon 20 insertion–positive non–small-cell lung cancer.

Sacituzumab govitecan showed anti-tumor activity in patients with pretreated metastatic or locally recurrent head and neck squamous cell carcinoma.

Treatment with BI 764532 produces a manageable safety profile among those with small cell lung cancer and neuroendocrine carcinoma in a phase 1 trial.

Treatment with zongertinib produces low rates of EGFR-mediated adverse effects among patients with HER2-mutated non–small cell lung cancer in the phase 1a/b BEAMION Lung-1 trial.

Treatment with loncastuximab tesirine-lpyl in the safety run-in portion of the LOTIS-5 study appears to be promising, according to Michal Kwiatek, MD, PhD

Investigators report no differences in rates of graft-versus-host-disease with intensive or non-intensive consolidation chemotherapy prior to transplantation for elderly patients with acute myeloid leukemia.

Eddy Saad, MD, explained how responses to immune checkpoint inhibitors can be elicited in patients with metastatic renal cell carcinoma.

In patients with metastatic renal cell carcinoma, neoadjuvant immunotherapy–based combinations yielded reductions in tumor size and pathologic necrosis at the time of cytoreductive nephrectomy.

Zanubrutinib and acalabrutinib produce similar safety profiles in the treatment of patients with relapsed/refractory chronic lymphocytic leukemia in the phase 3 ASCEND and APLINE trials.

mRNA-4157 plus pembrolizumab appears well tolerated without an increase in immune-mediated adverse effects vs pembrolizumab monotherapy among those with high-risk melanoma in the phase 2 KEYNOTE-942 trial.

Treatment with lisocabtagene maraleucel correlates with a reduction in CD19-positive cells in responders and patients with stable disease among those with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma in the phase 1/2 TRANSCEND CLL 004 trial.

Sintilimab plus chemoradiotherapy produces a higher 3-year distant metastasis-free survival rate vs chemoradiotherapy alone among patients with advanced nasopharyngeal carcinoma in the phase 3 CONTINUUM trial.

Nivolumab plus ipilimumab and chemotherapy also appears to produce a higher overall response rate compared with chemotherapy alone among those with squamous non–small cell lung cancer in the phase 3 CheckMate 9LA trial.

Treatment with tovorafenib appears well tolerated among pediatric patients with low-grade glioma, according to findings from the phase 2 FIREFLY trial.

Numerous patients with heavily pretreated relapsed/refractory multiple myeloma responded following treatment with talquetamab and daratumumab.

Luspatercept may lead to a paradigm shift in the treatment of patients with lower-risk myelodysplastic syndrome, according to an expert from The University of Texas MD Anderson Cancer Center.

Adavosertib does not appear to be well tolerated in patients with previously treated recurrent or persistent uterine serous carcinoma in the phase 2b ADAGIO trial.

An exploratory analysis indicates that overall survival did not improve with the use of single-agent atezolizumab in untreated locally advanced or metastatic urothelial cancer.

Patients diagnosed with locally advanced, hepatocellular carcinoma experience benefit in overall survival, progression-free survival, and time to disease progression following treatment with sorafenib and stereotactic body radiation therapy.

According to the phase 3 PERSIST-1 trial and PAC203 trial, thrombocytopenia was associated with myelofibrosis treatment.

Magrolimab in combination with azacitidine and venetoclax was well tolerated and yielded promising responses among patients with high-risk acute myeloid leukemia regardless of TP53 mutation status.

Everolimus failed to improve survival outcomes when added to adjuvant endocrine therapy in patients with HR+/HER2- breast cancer, according to findings from the phase 3 SWOG S1207 trial.

Findings from the phase 2 BIONIKK trial demonstrated an association between treatment efficacy and increased in situ and immune expression.

Results from the phase 3 IPSOS trial showed a nearly doubled rate of 2-year overall survival with atezolizumab in patients with advanced non–small cell lung cancer.

Pembrolizumab plus chemoradiation did not meet statistically significant improvement in event-free survival for patients with locally advanced head and neck squamous cell carcinoma.

A phase 3 study presented at 2022 ESMO showed progression-free survival benefit of nirogacestat over placebo for patients with progressive desmoid tumors.

Results from a phase 1b trial showed efficacy potential of sotorasib plus SHP2 inhibitor RMC-4630 for patients with pretreated or KRAS G12C inhibitor–naïve non–small cell lung cancer.